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Abstract
Background: A capillary network is needed in cancer growth and metastasis. Induction of angiogenesis represents
one of the major hallmarks of cancer. CDK11p58, a Ser/Thr kinase that belongs to the Cell Division Cycle 2-like 1
(CDC2L1) subfamily is associated with cell cycle progression, tumorigenesis, sister chromatid cohesion and
apoptotic signaling. However, its role in breast cancer proliferation and angiogenesis remains unclear.
Methods: Tumorigenicity assays and blood vessel assessment in athymic mice were used to assess the function
of CDK11p58 in tumor proliferation and angiogenesis. CCK-8 assay was used to detect breast cancer cell growth.
Immunohistochemistry was used to detect the expression of vascular endothelial growth factor (VEGF), CD31 and
CD34 in CDK11 positive patient breast cancer tissues. Dual-Luciferase array was used to analyze the function of CDK11p58
in the regulation of VEGF promoter activity. Western blot was used to detect related protein expression levels.
Results: CDK11p58 inhibited breast cancer growth and angiogenesis in breast cancer cells and in nude mice transplanted
with tumors. Immunohistochemistry confirmed that CDK11p58 was negatively associated with angiogenesis-related
proteins such as VEGF, CD31 and CD34 in breast cancer patients. Real-time PCR and dual-luciferase assay showed
CDK11p58 inhibited the mRNA levels of VEGF and the promoter activity of VEGF. As CDK11p58 is a Ser/Thr kinase, the
kinase-dead mutant failed to inhibit VEGF mRNA and promoter activity. Western blot analysis showed the same pattern
of related protein expression. The data suggested angiogenesis inhibition was dependent on CDK11p58 kinase activity.
Conclusion: This study indicates that CDK11p58 inhibits the growth and angiogenesis of breast cancer dependent on its
kinase activity.
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Background
Blood vessels deliver oxygen and nutrients to every part
of the body, but also nourish diseases such as cancer [1].
A capillary network from the surrounding host tissue is
needed both in cancer proliferation and in cancer metas-
tasis [2]. Angiogenesis is a physiological multi-step
process that includes endothelial cell growth and move-
ment [3]. Induction of angiogenesis represents one of
the major hallmarks of cancer [4], and plays important
roles in wound healing, endothelial cell-mediated deg-
radation of the extracellular matrix, and the transition of
benign tissues into solid tumors [5]. Therefore, there is a
great and urgent need to study the regulation and
elucidate the mechanisms of cancer angiogenesis. Vascu-
lar endothelial growth factor (VEGF) is a predominant
activator of endothelial cell functions such as new blood
vessel formation (angiogenesis) during development [6].
Through a VEGF-induced signaling pathway, VEGF plays
a vital role in the proliferation, migration, and invasion
of vascular endothelial cells. In addition, other growth
factors such as integrins, matrix metalloproteinases
(MMPs) and growth factor receptors (GFRs) also stimu-
late angiogenesis [1]. As previously reported, VEGF is an
important angiogenic factor in human breast cancer [7].
Microvessel density in areas of intense neovasculariza-
tion in invasive breast carcinoma is an independent and
highly significant prognostic indicator for overall and
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CDK11p58, a G2/M phase protein associated with cell
cycle progression and tumorigenesis [9], is a centrosome-
associated mitotic kinase involved in centrosome matur-
ation and bipolar spindle formation and is required for
centriole duplication and Plk4 recruitment to mitotic
centrosomes [10, 11]. Previously, we found that CDK11p58
inhibited the proliferation of prostate cancer and was
involved in regulation of androgen and estrogen signaling
[12–14]. In addition, our previous study demonstrated
that CDK11p58 inhibited ERα-positive breast cancer inva-
sion by targeting integrin β3 via the repression of ERα sig-
naling [15] and also we found breast cancers transfected
with CDK11p58 grew slowly compared with the control
cell lines, so we speculated that CDK11p58 might inhibit
the growth of breast cancer.
In the current study, we evaluated the direct anti-
tumor and anti-angiogenic effects of CDK11p58 in breast
cancer. An in vivo model of human breast cancer cell
xenografts in nude mice was used to assess the effects
and mechanism of CDK11p58 on tumor growth and
angiogenesis. We sought to determine the potential role
of CDK11p58 in breast cancer growth and angiogenesis
as well as the underlying mechanisms.
Methods
Samples
A tissue array including 32 breast cancer patient cancer-
ous tissues were obtained from the tissue bank of Fudan
University Shanghai Cancer Center in 2010. This study
was approved by the Ethical Committee of our Cancer
Center and written informed consent was obtained from
each patient.
Materials
Fetal bovine serum (FBS), Dulbecco’s modified Eagle
medium (DMEM), 1640 and expression vector pcDNA3.0
were purchased from Invitrogen (Invitrogen, USA). Mouse
and rabbit secondary antibodies for immunohistochemis-
try (IHC) were purchased from Cell Signaling (CST, USA).
Anti-HA and anti-CDK11 polyclonal antibodies were
purchased from Santa Cruz Biotechnology (Dallas, Texas,
USA). VEGF, CD31, CD34, integrin β3, mmp3 and mmp9
were all purchased from Epitomics Company (Abcam,
Cambridge, MA USA). Anti-GAPDH antibodies was pur-
chased from Proteintech (Beijing, China). A dual luciferase
reporter assay system was purchased from Promega
(Beijing, China).
Cell culture and cell transfections
293 T, MCF7, MDA-MB-231 and T47D cell lines were
obtained from our laboratory cell bank. 293 T, MCF-7
and T47D cells were grown using DMEM supplemented
with 10 % FBS, 100 μg/ml penicillin, and 100 μg/ml
streptomycin (Cat. 10378–016, Invitrogen) at 37 °C and
5 % CO2. MDA-MB-231 cells were cultured using F15
supplemented with 10 % FBS, 100 μg/ml penicillin and
100 μg/ml streptomycin at 37 °C and 5 % CO2. Transi-
ent transfection for luciferase assays was performed
using 96-well plates (1 × 104 cells per well) with 200 ng
of total plasmids and Lipofectamine 2000 reagent
(Cat.11668-019, Invitrogen) according to the manufac-
turer’s instructions.
Stable expression of CDK11p58 with retroviral vector
Human CDK11p58 was cloned into pBabe-puro vector for
ectopic expression of CDK11p58. MDA-MB231 and T47D
cells were infected with pBabe-puro vector control or
CDK11p58-overexpression virus and selected by Puro-
mycin. The expression levels of CDK11p58 in MDA-
MB231 and T47D were confirmed by Western blot assay.
Tumorigenicity assays and blood vessel assessment in
athymic mice
Female athymic BALB/c nu/nu mice, 4–6 weeks old,
were obtained from the Shanghai Institute of Materia
Medica, Chinese Academy of Sciences. All studies on
mice were conducted in accordance with the National
Institute of Health (NIH) ‘Guide for the Care and Use of
Laboratory Animals’. The study protocol was approved
by the Shanghai Medical Experimental Animal Care
Committee. Animals were divided into four groups:
MDA-MB-231/vector and MDA-MB-231/CDK11p58,
T47D/vector and T47D/CDK11p58. Each group con-
tained 16 mice. Cells (MDA-MB-231, 1.5 × 106 and
T47D, 1 × 107) were injected into the No.4 pairs of
mammary fat pad of mice. Animals were monitored
every 2 days for tumor growth and general health.
Tumor sizes were measured with caliper and calculated
by the formula V = (W) 2xL/2. Animals were sacrificed
and autopsied at 6 weeks after cell inoculation. To con-
firm the expression of the indicated proteins, sections
were cut at 50 μm intervals and stained with hematoxylin
and eosin (H&E) and by IHC.
For blood vessels imaging preparation, the image contrast
agent, barium sulfate suspended in glycerol (50 % water so-
lution; a concentration of 0.5 mg/mL), was injected into
the deeply anesthetized mouse ascending aorta. Then the
tumors were excised and fixed by 4 % paraformaldehyde
followed by graded ethanol. The microangiography for
blood vessels was performed at the Beamline BL13W1, the
biomedical application station of the Shanghai Synchrotron
Radiation Facility (SSRF) in China. The maximum light size
of the beam was 45 mm (horizontal) × 5 mm (vertical) at
the object position at 16 keV. Projections of tumor samples
in nude mice were then recorded using SSRF. The slice im-
ages were reconstructed using the filtered back projection
(FBP) algorithm. The vessels of tumor were segmented
from these slice images after reducing noise by using Gauss
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smoothing filter in Matlab. Moreover, thinning algorithm
was applied to extract the skeletons of vessels in order to
evaluate the status of tumor. After these image pre-
processing, micro vessel density (MVD), number of vessel
branches and number of vessel nodes were computed in
each tumor sample.
Cell counting kit-8 assay
Stable transfected cells were seeded in a 96-well plate at
5 × 103 cells per well and then cultured for 4 days. A
volume of 10 μl of CCK-8 (Cell Counting Kit-8, C0038,
Beyotime, Shanghai, China) solution was added to each well
of the plate and incubated at 37 °C for 4 h. The absorbance
at 450 nm was measured to represent the cell viability.
Immunohistochemistry
Expression levels of CDK11 (Sc-928, Santa Cruz, USA),
VEGF (ab46154, Abcam, USA), CD31 (GM082329, Gene-
Tech, Shanghai, China), and CD34 (GM716529, GeneTech)
in postoperative paraffin-embedded tumor specimens from
breast cancer patients and mice tumor tissues were de-
tected with IHC. The concentrations of antibodies used are
as follows: CDK11, 1:100; VEGF, 1:100; CD31, 1:50; and
CD34, 1:50. The Envision and diaminobenzidine (DAB)
Color Kit was purchased from Gene Tech Company Lim-
ited (Shanghai, China). The staining procedures strictly
followed the supplier’s recommendation. The staining index
(SI, range 0–9) was considered as the product of the inten-
sity score (0, no staining; 1+, faint/equivocal; 2+, moderate;
3+, strong) and the distribution score (0, no staining; 1+,
staining of <10 % of cells; 2+, between 10 % and 50 % of
cells; and 3+, >50 % of cells). For CDK11 protein in this
study, a moderate/strong staining (SI = 3–9) was defined as
positive or high staining, and a weak or negative staining
(SI = 0–2) was defined as negative or low staining.
In vitro angiogenesis model
Human Umbilical Vein Endothelial Cells (HUVEC),
which were obtained from our laboratory cell bank were
suspended in culture medium from stable cell lines and
then plated onto a thin layer (300 ml) of basement mem-
brane matrix (Matrigel; BD Biosciences) in 24-well plates
at 1 × 104 cells/well. After 12 h, the medium was removed,
cells were fixed, and images of cells were obtained with a
light microscope (Laica) at × 20 magnification. Quantifica-
tion of the tubular structures (anastomosing tubules) was
performed by counting the number of complete circles
produced by interlinking tubular HUVECs [16].
Dual luciferase reporter assays
293 T, T47D and MCF-7 cells were cotransfected with a
VEGF promoter luciferase reporter construct (100 ng)
[17], a control Renilla luciferase plasmid (pRL) (1 ng),
CDK11p58 or other mutants. Total plasmid DNA was
adjusted to 300 ng with an empty pcDNA vector. At
48 h post-transfection, a dual luciferase reporter gene
assay (Promega) was performed following the instruc-
tions using a SynergyHT Multi-Mode Microplate Reader
(BioTek, USA).
Western blot analysis
Cell pellets were lysed, protein extracts were quanti-
tated, loaded onto a 10 % sodium dodecyl sulfate–
polyacrylamide gel, electrophoresed, and transferred
to a nitrocellulose membrane. The membrane was in-
cubated with primary antibody, washed, and incubated
with horseradish peroxidase (HRP)–conjugated secondary
antibody (Cell Signaling). Detection was performed usig
chemiluminescent Western detection kit. GAPDH was
using as a loading control. The quantification of immuno-
blotting was done by the Photoshop Software.
Statistical analysis
Results are either representative or are the mean of at least
three independent experiments performed in triplicate.
Statistical analysis was performed using ANOVA test and
Student’s t-test for unpaired data (Prism, GraphPad). Chi-
squared test analyses were performed using SPSS (version
19.0; SPSS Company). P < 0.05 was considered statistically
significant.
Results
CDK11p58 inhibits the growth of breast cancer
To evaluate the role of CDK11p58 in breast cancer, we
first constructed CDK11p58 stable breast cancer cell lines
in ER negative MDA-MB231 and ER positive T47D.
Western blot assay showed that CDK11p58 was more
highly expressed in the two stable cell lines than the
control pBABE group and wild type group (Fig. 1a). By
Cell Counting Kit-8 assay, we found that CDK11p58
inhibited breast cancer cell gowth compared with the
pBABE control both in MDA-MB231 and T47D cells
(Fig. 1b). Colony formation assay was used to examine
the effect of CDK11p58 in tumorigenesis and also dem-
onstrated that CDK11p58 inhibited the growth and
tumorigenesis of breast cancer cells (Fig. 1c, Additional
file 1: Figure S1A).
Then we further investigated the role of CDK11p58
in tumor growth by using an in vivo orthotopic xeno-
graft tumor model in athymic mice. MDA-MB-231/
vector/CDK11p58 or T47D/vector/CDK11p58 cells were
injected into the No. 4 mammary fat pad of athymic
mice. At 6 weeks, we measured the size of tumors
and monitored tumor cell growth. CDK11p58 inhibited
in vivo tumor growth significantly (Fig. 1d, Additional
file 1: Figure S1B).
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Fig. 1 (See legend on next page.)
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CDK11p58 inhibits the angiogenesis of breast cancer
In the nude mice tumor model, we detected the cancer
tissue expressions of CDK11p58, VEGF, CD31 and CD34
by IHC. CDK11p58 expression was significantly high in the
stable expression group. CDK11p58 inhibited the expres-
sion of VEGF, CD31 and CD34 in breast tumors com-
pared with the control group (Fig. 2a). Because VEGF is
involved in promoting breast cancer angiogenesis, pseudo-
capillary formation in matrigel with HUVECs was first
measured using the conditioned media of the two series of
breast cancer cells. CDK11p58 stable expression and con-
trol breast cancer cells were cultured for 48 hours, then
the conditioned medias were obtained. When plated in a
thin layer of matrigel and stimulated with the conditioned
medias, HUVECs were organized in a network of pseudo-
capillary tubes that invaded the gel (Fig. 2b). CDK11p58
treatment reduced the number of pseudocapillaries in
terms of completed circles in MDA-MB-231 and T47D
Fig. 2 CDK11p58 inhibits the angiogenesis of breast cancer. (a) Association of CDK11p58 expression and VEGF expression in breast cancer in nude
mice. Immunohistochemical staining for the expression of CDK11, VEGF, CD31, CD34 in human breast cancer tissues. (b) Representative pictures
of pseudocapillary formation in matrigel from HUVECs in 0.1 % FBS exposed to breast cancer cell culture at 12 h after cell seeding. (c) Quantification of
pseudocapillaries obtained by counting numbers of complete circles/wells. Numbers represent the mean of 6 samples ± SEM of three experiments run
in triplicate. (d) CDK11p58 inhibits the vascularization of MDA-MB231 xenograft tumors in mice. The images were reconstructed using the filtered back
projection (FBP) algorithm. (e) Quantitative analysis of angiogenesis of MDA-MB231 xenograft tumors in implants. For each condition (n = 6), the means
of 6 samples ± SD are shown. **P < 0.01, CDK11p58 group compared to the pBABE group
(See figure on previous page.)
Fig. 1 CDK11p58 inhibits the proliferation of breast cancer. (a) CDK11p58 expression was detected by western blot assay in a CDK11p58 stable cell
line in MDA-MB231 and T47D cells. (b) CCK-8 proliferation analysis of CDK11p58 stable transfected breast cancer cells MDA-MB231 and T47D compared
with controls. (c) Colony formation of human breast cancer cells stably transfected with CDK11p58 or pcDNA3.0. **P < 0.01. (d) Tumorigenesis after
injection of MDA-MB231 cells stably expressing CDK11p58 or control pBABE. Growth curve with CDK11p58 stable expression and controls was
also shown
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(Fig. 2c for quantification). These data suggest that
CDK11p58 inhibited pseudocapillary formation in both
MDA-MB231 and T47D.
Blood vessels of tumors were then examined. As shown
in Fig. 2d and e, the density of blood vessels in MDA-
MB231 tumors was attenuated significantly in tumors
expressing high levels of CDK11p58 relative to control
groups (Table 1). Both tumor size and the MVD (mi-
cro-vascular density) were inhibited by CDK11p58 in
the MDA-MB231 group (Fig. 2d, e) and T47D groups
(Additional file 1: Figure S1C). In addition, the vessel
branches and nodes in the tumors were attenuated by
CDK11p58. These data suggest that CDK11p58 inhibited
breast tumor angiogenesis and proliferation in vivo.
CDK11p58 is associated with decreased angiogenesis in
breast cancer patients
To determine further whether CDK11p58 was involved
in the regulation of angiogenesis in breast cancer, 32
breast cancer patient tumor tissues were used to exam-
ine the expression of CDK11p58 and angiogenesis related
factors. VEGF, CD31, CD34 and CDK11p58 were exam-
ined by tissue array. CDK11p58 was expressed both in
the nucleus and cell plasma. VEGF was expressed mainly
in plasma. CD31 and CD34 were expressed specifically
in vascular endothelial cells (Fig. 3). By IHC, we also
observed high CDK11 expression in 18 cases and low
expression in 14 cases. In the same patients’ tissues, high
VEGF expression was observed in 15 cases and low
expression was observed in 15 cases. The expression
pattern of CDK11 was opposite to that of VEGF, CD31
and CD34 staining. The value of Chi-squared test for the
correlation between CDK11 and VEGF was 10.041 and
the P value was less than 0.01 (Table 2). The clinical data
supported the negative association of CDK11p58 with
VEGF and demonstrated CDK11p58 inhibited angiogenesis
in breast cancer.
CDK11p58 inhibits angiogenesis by inhibition of the VEGF
signaling pathway
To examine the regulation of VEGF by CDK11p58, VEGF
mRNA was detected by qRT-PCR. VEGF mRNA was
inhibited by CDK11p58 both in MDA-MB231 and in
T47D (Fig. 4a). Promoter activity of VEGF assessed by
Dual luciferase assay in 293 T demonstrated that
CDK11p58 decreased the promoter activity of VEGF
compared with the control in a dose dependent manner
(Fig. 4b). In addition, CDK11p58 inhibited the protein ex-
pression of VEGF, CD31, and other angiogenesis-related
protein integrin β3 (ITGB3) (Fig. 4c, the normalized
quantification of immunoblotting data was shown in the
Additional file 1: Figure S2A). CDK11p58 is a Ser/Thr
kinase and whether inhibition was dependent on its kin-
ase activity was then examined. T370A and D224N are
CDK11p58 kinase dead mutants whereas T370D is a
kinase-activated mutant as previously reported [12, 18].







T47D pBabe 18381 8000 1.5194 0.1465 17.6 138.22
T47D CDK11p58 7418 2943 0.4365 0.0984 13.43 73.01
231 pBabe 23560 10341 1.4792 0.891 17.71 123.31
231 CDK11p58 10166 3960 0.8135 0.0927 15.09 98.07
OD: Outside Diameter, MVD: Micro-vessel Density, Size: Tumor sample size,
Branches: vessel branches, Nodes: vessel nodes
Fig. 3 Association of CDK11p58 expression and VEGF expression in
human breast cancer. Immunohistochemical staining for the expression
of CDK11, VEGF, CD31, CD34 in human breast cancer tissues
Table 2 Correlation of CDK11p58 and VEGF levels in breast
cancer patients
n VEGF expression ×2 p
Positive (%) Negative (%)
CDK11 positive 18 4 (12.5 %) 14 (43.7 %) 10.041 0.004
CDK11 negative 14 11 (34.4 %) 3 (9.4 %)
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However, T370A and D224N lost the inhibitory ability
but promoted the activity of the VEGF promoter
(Fig. 4d). These data suggest that CDK11p58 inhibited
the promoter activity of VEGF in a kinase dependent
manner. Western blotting also showed that CDK11p58
inhibited the expression of VEGF, CD31 and integrin
β3 proteins in a kinase dependent manner in MDA-
MB231 cells (Fig. 4e, the normalized quantification of
immunoblotting data was shown in the Additional file 1:
Figure S2B). Taken together, these data suggest that
CDK11p58 inhibited angiogenesis through VEGF signaling
in a kinase dependent way.
Discussion
In this study, we focused on the critical role of CDK11p58
in breast cancer growth and angiogenesis, especially the
regulation of VEGF by CDK11p58 and the dependence on
its kinase activity. First, we determined that CDK11p58
inhibited the growth and formation of pseudocapillaries in
breast cancer cells. Using a nude mouse model,
CDK11p58 inhibited the growth and density of microves-
sels of the transplanted tumor. Second, by mice tumor
tissues, we used IHC to determine a negative association
of the expression of VEGF, CD31, and CD34 as well as
MVD status with CDK11 expression. Similar results were
Fig. 4 Regulation of VEGF signaling by CDK11p58. (a) qRT-PCR analysis of VEGF mRNA in breast cancer cells MDA-MB-231 and T47D. **P < 0.01
CDK11p58 group vs control group. (b) After transfection of CDK11p58 expression for 48 h, luciferase activity of VEGF promoter reporters was
detected in 293 T cells. **P < 0.01 CDK11p58 vs control vector. (c) Western blot analysis of angiogenesis-related proteins by CDK11p58. (d) The
luciferase activity of VEGF promoter reporters with CDK11p58 expression and CDK11p58 mutant expression in T47D cells. (e) Western blot analysis
of angiogenesis related proteins by CDK11p58 and its mutations in MDA-MB231
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observed in human breast cancer tissues. Then, we de-
tected the regulation of VEGF by CDK11p58 both in 293 T
cells and breast cancer cells. CDK11p58 inhibited the pro-
moter activity of VEGF regulation at the transcriptional
level and constantly inhibited angiogenesis-related protein
expression in a kinase dependent manner.
Breast cancer is the most common female cancer and
among the most frequent causes of cancer mortality in
women worldwide [19, 20]. Cancer can spread through
tissues, the lymph system and the blood [21]. Breast can-
cer is prone to travel through the blood vessels to other
parts of the body, mainly to the brain, bone and lung
[22–24]. Angiogenesis is a critical process in tumor
growth and metastasis [25]. VEGF family members are
involved in the regulation of angiogenesis. VEGF is the
main component of this family and stimulates angiogen-
esis in health and disease by signaling through VEGF
receptor-2 [3, 26]. Thus far, the VEGF-neutralizing anti-
body bevacizumab (Avastin) is used for metastatic colo-
rectal, metastatic breast cancer and other metastatic
cancers [25].
CDK11p58 is involved in a variety of important regula-
tory pathways in eukaryotic cells, including cell cycle
control, apoptosis, neuronal physiology, differentiation
and autophagy [10, 27–31]. It is a Ser/Thr kinase and
most of its functions are dependent on its kinase activity
[32]. In our previous study, we found that CDK11p58 re-
pressed ERa transcription activity by promoting its
ubiquitin-proteasome degradation in breast cancer [13].
In this study, we found that CDK11p58 inhibited the
growth and angiogenesis not only in breast cancer cells
but also in a nude mouse breast tumor model. This
revealed that CDK11p58 might act as a tumor suppressor
in breast cancer.
In the nude mouse cancer model and in the breast can-
cer patient samples assessed by IHC, we also found that
CDK11p58 expression was negatively associated with
angiogenesis related proteins VEGF, CD31 and CD34.
Similar results were obtained in breast cancer cells. These
data suggest that CDK11p58 might inhibit tumor prolifera-
tion and progression by an influence on angiogenesis.
As VEGF predominately regulates angiogenesis and
several studies reported that targeting VEGF gene
could inhibit the proliferation and induce the apop-
tosis of human breast cancer cells and in mice
models [33–35], we speculated that CDK11p58 might
inhibit angiogenesis through the regulation of VEGF.
To confirm further the roles of CDK11p58 and VEGF,
the mRNA levels of VEGF were examined at different
levels of CDK11p58. We found that CDK11p58 inhibited
VEGF mRNA and promoter activity of VEGF. These
results indicated that CDK11p58 inhibited the angiogenesis
of breast cancer by inhibiting the promoter activity of
VEGF in a dose dependent manner. Based on our
previous study, CDK11p58 could also induce the apoptosis
of cancer cells through blocking the cells into the G2/M
cell phase. So the mechanism involved in the growth and
angiogenesis inhibition function of CDK11p58 should be
complicated and not only dependent on the VEGF path-
way. It needs further investigation.
As CDK11p58 is not a transcription factor, we spec-
ulated that VEGF promoter activity was indirectly in-
fluenced by CDK11p58. CDK11p58 might function as a
co-repressor or regulate related transcription factors.
The exact mechanism requires further investigation.
In addition, CDK11p58 inhibited the protein expres-
sion of VEGF, CD31, and integrin β3. Several reports
revealed that some breast cancer cells acquired CD31
expression [36]. CD31 expression mainly correlates
with tumor cells spreading within the ductal system
[37]. Additionally, CD31 can effluence the growth and
differentiation of human breast cancer cells. Despite
the expression level is relatively low in the breast
cancer cells we investigated, CDK11p58 further inhib-
ited its expression. Along with VEGF, it could further
explain the inhibition effect of growth and angiogen-
esis by CDK11p58.
In our previous study, it showed that CDK11p58 could
promote the ubiquitin–proteasome degradation of ER
alpha [13]. In this study, the data showed that CDK11p58
inhibited the tumor growth and angiogenesis both in
MDA-MB-231 ER-negative cells and in T47D ER-
positive cells. Also, we found CDK11p58 inhibited VEGF
promoter activity in MDA-MB-231, T47D and 293 T
cells. So we speculated that it was ER independent.
CDK11p58 inhibited the tumor growth and angiogenesis
in an ER independent way.
CDK11p58is a Ser/Thr kinase and most of its func-
tions are kinase-dependent. Thus, we hypothesized that
VEGF inhibition was also CDK11p58 kinase dependent.
Because we previously showed that Thr370 of
CDK11p58 was responsible for CDK11p58 autophospho-
rylation, dimerization and kinase activity, mutant
T370D and T370A were constructed. In addition, the
mutant D224N was reported to be a kinase dead mu-
tant. Indeed, the kinase constantly activated mutant
T370D significantly inhibited the VEGF promoter activ-
ity compared with the kinase-dead mutant T370A and
D224N. The same pattern was obtained at the protein
level. These data suggest that the VEGF signaling
pathway is inhibited by phosphorylation triggered by
CDK11p58 and that CDK11p58 inhibits angiogenesis
through VEGF signaling in a kinase dependent manner.
CDK11p58 could function through phosphorylating
some substrates to be involved in the regulation of
VEGF transcription. Base on this result, we will further
investigate its mechanism through finding CDK11p58
substrates by MS analysis.
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Conclusions
Taken together, our data show that CDK11p58 inhibits
the growth and angiogenesis of breast cancer through
inhibiting the regulation of VEGF signaling in a kinase
activity dependent manner.
Additional file
Additional file 1: Figure S1. (A) Colony formation of T47D cells stably
transfected with CDK11p58 or pcDNA3.0. (B) Tumorigenesis after injection
of T47D cells stably expressing CDK11p58 or control pBABE. Growth curve
with CDK11p58 stable expression and controls was also shown below.
(C) CDK11p58 inhibits the vascularization of tumors of T47D in mice.
Figure S2. (A) Western blot analysis of angiogenesis-related proteins by
CDK11p58. The normalized quantification of immunoblotting data from
triplicate experiments were shown as below. (B) Western blot analysis
of angiogenesis related proteins by CDK11p58 and its mutations. The
normalized quantification of immunoblotting data from triplicate experiments
were shown as below. *p < 0.05; **p< 0.001. (DOC 1612 kb)
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